Skip to main content

Bain Capital Life Sciences — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

59
Companies
$10.0B
Total invested
$169.7M
Avg. check
16
Industries
Biotechnology 20Health Care 16Medical 10Pharmaceutical 9Therapeutics 9Life Science 6+10 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 1–24 of 59
OMass Therapeutics
October 2026

OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics.

Biotechnology · Oxford$310.0M Series C
ADC Therapeutics
October 2026

ADC Therapeutics develops antibody drug conjugates and non-antibody drug conjugate products.

Biopharma · Lausanne$86.6M Post-IPO Equity
AdvanCell
July 2026

AdvanCell develops targeted alpha radiopharmaceutical therapies for cancer and supports their development and manufacturing.

Biotechnology · Sydney$315.0M Series D
CereVasc
June 2026

CereVasc is a medical device company that develops a minimally invasive treatment option for communicating hydrocephalus.

Biotechnology · Charlestown$85.0M Series C
Apreo Health
May 2026

Apreo Health is developer of medical apparatus designed for diagnosing or treating respiratory, pulmonary, and lung conditions.

Health Care · Menlo ParkVenture - Series Unknown
Pharvaris
May 2026

Pharvaris is a clinical-stage biomedical company focused on bringing oral bradykinin B2-receptor antagonists to patients.

Biotechnology · Zug$132.3M Post-IPO Equity
Cabaletta Bio
May 2026

Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.

Biotechnology · Philadelphia$150.0M Post-IPO Equity
Imperative Care
March 2026

Imperative Care is singularly dedicated to finding meaningful answers to unsolved problems in stroke.

Health Care · Campbell$100.0M Convertible Note
Xilio Therapeutics
February 2026

Xilio Therapeutics is a biotechnology company that develops tumor-activated immuno-oncology therapies.

Biopharma · Waltham$40.0M Post-IPO Equity
Century Therapeutics
January 2026

Century Therapeutics is a biotechnology company that develops cell therapies for hematological and solid tumor malignancies.

Biotechnology · Philadelphia$135.0M Post-IPO Equity
Kestra Medical Technologies, Inc.
December 2025

Kestra Medical Technologies offers wearable medical devices which collects, store, and communicate patients vital performance data.

Health Care · Kirkland$138.0M Post-IPO Equity
Nuvalent
November 2025

Nuvalent is a biopharmaceutical company that develops targeted therapies for cancer by designing small-molecule medicines.

Biotechnology · Cambridge$500.0M Post-IPO Secondary
X4 Pharmaceuticals
October 2025

X4 Pharmaceuticals is a clinical-stage oncology company developing oral small molecule CXCR4 antagonists for the treatment.

Biotechnology · Cambridge$155.3M Post-IPO Equity
Amylyx Pharmaceuticals
September 2025

Amylyx Pharmaceuticals specializes in providing solutions for Alzheimer’s and other diseases of the brain.

Biotechnology · Cambridge$175.0M Post-IPO Equity
Merida Biosciences
April 2025

Merida Biosciences is a biotech company focused on developing precision treatments, particularly for autoimmune diseases.

Biotechnology · Cambridge$121.0M Series A
Heartflow
March 2025

Heartflow is a medical technology company that provides various methods of diagnosis and treatment of cardiovascular disease.

Artificial Intelligence (AI) · Mountain View$98.0M Convertible Note
Rivus Pharmaceuticals
January 2025

Rivus Pharmaceuticals operates as a biopharmaceutical company dedicated to improving cardio-metabolic health.

Biotechnology · Charlottesville$57.0M Venture - Series Unknown
Timberlyne Therapeutics
January 2025

Timberlyne Therapeutics is a biopharmaceutical company that develops therapies for autoimmune diseases.

Biopharma · San Diego$180.0M Series A
New Amsterdam Pharma
December 2024

New Amsterdam is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.

Biotechnology · Naarden$452.6M Post-IPO Equity
Replimune Group
November 2024

Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the treatment of cancer.

Biotechnology · Woburn$140.0M Post-IPO Equity
Serán Bioscience
September 2024

Serán Bioscience is a contract development and manufacturing organization.

Biotechnology · Bend$200.0M Private Equity
Cardurion Pharmaceuticals
July 2024

Cardurion is a cardiovascular biotechnology company developing therapeutics for the treatment of heart failure and cardiovascular diseases.

Biotechnology · Boston$260.0M Series B
Areteia Therapeutics
February 2024

Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease.

Biotechnology · Bernardsville$75.0M Series A
Syremis Therapeutics
December 2025

Syremis Therapeutics is developing novel medicines to make a profound impact on the treatment of mental health disorders.

Health Care · Tel Aviv$165.0M Series A

Where Bain Capital Life Sciences invests

Biotechnology20
Health Care16
Medical10
Pharmaceutical9
Therapeutics9
Life Science6

About Bain Capital Life Sciences's portfolio

How many companies has Bain Capital Life Sciences invested in?▸

Bain Capital Life Sciences has invested in 59 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Bain Capital Life Sciences invest in?▸

Bain Capital Life Sciences's top investment sectors include Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics. The firm invests across 16 different industry categories.

What is Bain Capital Life Sciences's largest investment?▸

Among tracked funding rounds, Nuvalent received $500.0M in a Post-IPO Secondary round. Bain Capital Life Sciences's total known invested capital is $10.0B.

What is the average investment size for Bain Capital Life Sciences?▸

Bain Capital Life Sciences's average investment size is $169.7M across its portfolio of 59 companies.

What are Bain Capital Life Sciences's most recent investments?▸

Recent Bain Capital Life Sciences portfolio additions include OMass Therapeutics, ADC Therapeutics, AdvanCell, CereVasc, Apreo Health. These companies were founded in 2020 or later.

Reach the founders behind these 59 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →